Spanish pharmaceutical company Almirall reported second-quarter 2026 earnings that fell short of market expectations, with a notable deceleration in sales growth for its flagship dermatology treatment, Ebglyss. The profit miss, confirmed by the company on July 24, 2026, was approximately 8% below consensus estimates. This slowdown introduces significant uncertainty into the company's previously stated full-year growth trajectory and has prompted a reassessment of its product portfolio's momentum.
Context — why this matters now
Almirall has positioned Ebglyss as a cornerstone of its growth strategy since its successful launch in the atopic dermatitis market. The drug's rapid uptake in previous quarters had allowed the company to project confident revenue guidance for 2026. The current macroeconomic environment for European healthcare stocks is challenging, with the STOXX Europe 600 Health Care index down 4% year-to-date amid pressures from drug pricing reforms and higher regulatory scrutiny.
The trigger for this earnings disappointment appears to be increased competitive pressure in the immunology space. Rival products from larger pharmaceutical firms have intensified their marketing efforts and secured additional formulary placements in key European markets. This competitive dynamic has eroded Ebglyss's new prescription growth rate faster than analysts had modeled, catching the market by surprise and occurring just as investors were looking for confirmation of the drug's long-term blockbuster potential.
Data — what the numbers show
Almirall's Q2 2026 net profit reached €42 million, falling short of the €45.6 million consensus forecast from analysts. Revenue for the quarter was €255 million, with Ebglyss contributing €78 million. This represents a quarter-over-quarter growth rate for Ebglyss of just 5%, a sharp decline from the 18% sequential growth recorded in Q1 2026.
The company's overall product portfolio performance is shown in the table below, highlighting the reliance on Ebglyss.
| Product | Q2 2026 Revenue (€M) | Quarterly Growth |
|---|
| Ebglyss | 78 | +5% |
| Rest of Portfolio | 177 | +1% |
This slowdown contrasts with the performance of a peer, Danish dermatology specialist LEO Pharma, which reported a 7% year-over-year increase in its immunology portfolio in its last update.
Analysis — what it means for markets / sectors / tickers
This earnings miss places immediate pressure on European mid-cap pharmaceutical stocks [SXDP]. Investors may reprice similar companies like Galapagos [GLPG] and Argenx [ARGX], which also depend on single-product growth stories, leading to potential multiple contractions of 3-5% in the near term. Conversely, larger peers with diversified portfolios, such as Novartis [NOVN] and Sanofi [SAN], may be viewed as safer havens, potentially attracting capital away from the mid-cap segment.
A key limitation to this bearish read-through is that Almirall's underlying prescription volume for Ebglyss remains positive, suggesting the issue may be primarily pricing or rebating pressure rather than a fundamental loss of physician confidence. Trading flow data indicates a buildup of short interest in the days leading to the earnings release, with institutional sellers outpacing buyers by a ratio of nearly 2-to-1. This positioning suggests the market was partially anticipating a negative catalyst.
Outlook — what to watch next
Investors should monitor Almirall's next business update, scheduled for October 29, 2026, for any revision to its full-year Ebglyss sales guidance. The key level to watch is the €80 million quarterly revenue threshold for the drug; a failure to break above it in Q3 would confirm a sustained growth problem.
Upcoming regulatory decisions from the European Medicines Agency on label expansions for Ebglyss in new indications, expected in Q4 2026, represent another critical catalyst. If approved, these expansions could revitalize growth, but delays or rejections would compound the current negative sentiment. The 50-day moving average for Almirall's share price, currently around €19.50, will act as a near-term resistance level.
Frequently Asked Questions
What does Almirall's earnings miss mean for retail investors?
For retail investors, the profit miss highlights the risks of investing in companies heavily reliant on a single product. The stock's volatility is likely to increase as the market digests the new growth narrative. It underscores the importance of diversification within the healthcare sector and paying close attention to competitive dynamics during quarterly earnings calls, which can be found in our analysis of biotech earnings.
How does Ebglyss's slowdown compare to other drug launches?
The slowdown is reminiscent of the growth plateau experienced by Sotyktu (deucravacitinib) from Bristol Myers Squibb in the psoriasis market after its initial launch surge. In that case, rapid initial adoption was followed by a sharp deceleration as competitors responded with their own clinical data and marketing campaigns, ultimately leading to revised, lower peak sales estimates from analysts.
What is the historical context for a 5% quarterly growth rate in pharmaceuticals?
A 5% sequential quarterly growth rate for a drug in its commercial expansion phase is considered modest. Successful blockbuster drugs typically maintain double-digit quarterly growth for at least the first six to eight quarters post-launch. For context, Dupixent (dupilumab) maintained an average quarterly growth rate of over 15% for its first three years on the market in similar indications.
Bottom Line
Almirall's growth story is now contingent on reversing Ebglyss's slowdown or diversifying its revenue base.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
